Antibody catalog

EEA1, or Early Endosome Antigen 1 is a Rab5 effector essential for early endocytic membrane fusion. The EEA1 antibody is used in membrane trafficking and chaperone studies, and as an endosome marker. We at Novus Biologicals have a comprehensive antibody catalog of EEA1 products.

C-Myc is a widely expressed transcription factor, regulating cellular differentiation, proliferation, cell cycle progression and pro-apoptotic gene expression. The c-Myc antibody is widely used in cancer research, as a number of human tumors have been attributed to altered c-Myc expression.

CD4 is a member of the cluster of differentiation family of proteins, mainly expressed on the surface of thymocytes and a specific subset of mature T-cells. CD4 antibody studies have also shown it expressed on monocytes, cortical cells, microglial cells, dendritic cells and macrophages. The CD4 antibody is widely used in cell marker studies, CD4 being one of the most common CD markers in use.

The ABCA1 (ATP-binding cassette transporter-A1) gene encodes a transmembrane protein, which plays a major role in phospholipid homeostasis by regulating cholesterol efflux from the cell. ABCA1 antibody studies have shown ABCA1 expression is up/down regulated by the transcription factors LXR and SREBP2 respectively.

The end of March has proven to be a busy time for the Novus antibody lab. Seven new antibodies were launched, numerous antibody conjugations completed, and continuous quality control testing of new antibody lots.

The Novus Product Development Team is excited to announce the launch of a new antibody target not currently available by any other antibody suppliers. The two new antibodies, a human TMEM97 antibody (NBP1-30436) and mouse TMEM97 antibody (NBP1-30437) are of particular interest as TMEM97 is implicated in several cancers, including breast, pancreatic, colorectal and ovarian cancers.

Not everyone knows how antibodies influence animal life, so this article is, in part, a very brief introduction. Novus Biologicals offers a printed version of their Apoptosis Catalog that contains additional information on apoptotic mechanisms; email promotions@novusbio.com to get a copy.

We have seen that antibody research can deliver progress in areas where other methods have not enjoyed such success.

Autism is a condition which demands more research - even if some autistic people do not want their condition to be ‘cured’, most would like some of their symptoms to be alleviated.

Fatemi and colleagues (J Autism Dev Disord. 2009, 39(2) pp. 223–230) subjected brain tissue from autistic and control subjects to SDS-PAGE followed by Western blotting and incubation with antibodies to four GABA-A receptor subunits.

Researchers can manipulate antibodies to yield very impressive research outcomes, which may prove highly relevant to the medical treatment of the future.

Severson et al (MBC 2009, 20(7) pp. 1916-1925) used antibodies, including monoclonal rabbit anti-JAM-A and monoclonal rabbit anti-β1 integrin from Novus Biologicals to investigate epithelial cell migration.